The regulatory role of DPP4 in atherosclerotic disease

Cardiovascular Diabetology

Review

Sanjay Rajagopalan¹  Xiaoquan Rao¹  Jixin Zhong¹  Chang Xia²  Lihua Duan³ 

[1] Cardiovascular Research Institute, School of Medicine, Case Western Reserve University, 2103 Cornell Rd., Wolstein Research Building 4525, 44106, Cleveland, OH, USA;Cardiovascular Research Institute, School of Medicine, Case Western Reserve University, 2103 Cornell Rd., Wolstein Research Building 4525, 44106, Cleveland, OH, USA;Department of Microbiology and Immunology, Wuhan Polytechnic University, 430023, Wuhan, Hubei, China;Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, 361003, Xiamen, Fujian, China;Cardiovascular Research Institute, School of Medicine, Case Western Reserve University, 2103 Cornell Rd., Wolstein Research Building 4525, 44106, Cleveland, OH, USA;

关键词: Dipeptidyl peptidase;    Gliptins;    Atherosclerosis;    Incretin;    DPP4 inhibitor;   

DOI  :  10.1186/s12933-017-0558-y

 received in 2017-03-07, accepted in 2017-06-02,  发布年份 2017

来源: Springer

【 摘 要 】

The increasing prevalence of atherosclerosis has become a worldwide health concern. Although significant progress has been made in the understanding of atherosclerosis pathogenesis, the underlying mechanisms are not fully understood. Recent studies suggest dipeptidyl peptidase-4 (DPP4), a regulator of inflammation and metabolism, may be involved in the development of atherosclerotic diseases. There has been increasing clinical and pre-clinical evidence showing DPP4-incretin axis is involved in cardiovascular disease. Although the cardiovascular outcome of DPP4 inhibition or incretin analogues has been or being evaluated by several large scale clinical trials, the exact role of DPP4 in atherosclerotic diseases is not completely understood. In the current review, we will summarize the recent advances in direct and indirect regulatory role of DPP4 in atherosclerosis.

【 授权许可】

CC BY   
© The Author(s) 2017